ArticleAntibiotics (Basel, Switzerland)2022
Low Level of Colistin Resistance and
Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Rectal Bacteria and Antibiotic Resistance in Zoo Animals in Algeria.Antibiotics (Basel, Switzerland) · 2026Article
- Occurrence of colistin-resistant Escherichia coli in yellow-legged seagulls (Larus michahellis) from Central Italy.Veterinary research communications · 2026Article
- Antimicrobial Resistance and Genomic Characterization of FourAntibiotics (Basel, Switzerland) · 2026Article
- Antimicrobial peptide resistance in Salmonella AMR: the role of surface binding and lipopolysaccharide remodelling: one health implications.World journal of microbiology & biotechnology · 2026Review
- Genomic epidemiology and resistome dynamics ofFrontiers in microbiology · 2025Article
- Molecular Evaluation of Expression Changes in Genes Associated With Colistin Resistance and Virulence Development inThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Article
- Article
- Unraveling the genome-wide repertoire of the novel chromosomally encodedFrontiers in microbiology · 2025Article
- Phenotypic and Genotypic Characterization ofAntibiotics (Basel, Switzerland) · 2024Article
- Detection ofAntibiotics (Basel, Switzerland) · 2024Article
- Recommendation of a standardized broth microdilution method for antimicrobial susceptibility testing ofJournal of clinical microbiology · 2024Article
- Plasmid-encoded lactose metabolism and mobilized colistin resistance (Microbial genomics · 2023Article
- Editorial for the Special Issue: Colistin Resistance-The Need for a One Health Approach.Antibiotics (Basel, Switzerland) · 2022Article
- Occurrence ofFrontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Salmonellosis is one of the most important zoonoses in Europe and the world. Human infection may evolve in severe clinical diseases, with the need for hospitalization and antimicrobial treatment. Colistin is now considered an important antimicrobial to treat infections from multidrug- resistant Gram-negative bacteria, but the spreading of mobile colistin-resistance (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.